Prognostic value of baseline G8 geriatric assessment in a real-life population of elderly metastatic colorectal cancer patients: The Gold Study.

• DOI: 10.1200/jco.2022.40.16_suppl.e24015
• Publication Date: 2022-06-06T17:46:10Z
• Authors: Giulia Maddalena; Alessandra Prete; Federica Buggin; Fable Zustovich; Jessica Cadau; Giuseppe Azzarello; Letizia Procaccio; Caterina Soldà; Mario Domenico Ri...; Cosimo Rasola; Claudia Galante; Eleonora Bergo; Silvia Montelatici; Ciro Longobardi; Giorgia Boscolo; Filomena Graziani; Luca Boni; Sara Lonardi; Vittorina Zagonel; Francesca Bergamo
• Keywords: Clinical endpoint; Geriatric oncology

e24015 Background: Colorectal cancer (CRC) is the second most frequent malignancy in patients (pts) aged 70. Elderly are often excluded by clinical trials; however, improvements quality of life and comorbidities management led to expand access anticancer treatments irrespectively age per se. Finding new tools stratify vulnerability elderly pts crucial guide clinicians therapeutic decisions. G8 timed up go test (TUG) have been related prognosis functional decline affected several solid tumors. However, no studies focused on TUG prognostic value CRC available. In this study, we assessed a cohort real-life with metastatic (mCRC). Methods: GOLD was multicentre, observational, prospective study which 70 mCRC eligible 1 st line therapy were enrolled. performed at screening first documented disease progression (PD). cutoff 14, as reported literature; TUG8,5 sec (cutoff set ROC curve using MedCalc software v 20.027). PFS OS described Kaplan-Meyer curve. All analyzed variables then compared multivariate models. Primary endpoint assess PFS. Secondary endpoints Results: Since Oct 2017 Apr 2019, 109 evaluated 4 different Oncology Units Veneto (IT); not where thus excluded. 105 finally Clinical, histological molecular characteristics well balanced between G814 vs > 14, exception RASmut, more represented 14 group (p = 0,0195). 39 (37%) aged80; 46 (44%) had ECOG PS1; 55 (53%) RASmut; 15 (15%) BRAFmut. 81 (77%) G814; 78 (75%) TUG8,5. At median follow time 41,2 months, 19,41 months (95%CI 15,46-23,19) 8,78 (95% CI 7,53-10,07). longer (HR 0,61; 95%CI 0,39-0,97; p= 0,0584) 0,55; 0,35- 0,86; 0,0201). influenced 0,55-1,34; 0,5125) nor 0,71; 0,47-1,08). conferred better also subgroup RASmut (respectively 0,0133 0,0088). Worse observed presence site 1,71; 1,11 2,64; 0,0161). analysis, ( 0,0202) single 0,0200) OS; none analysed effect Conclusions: our OS, but PFS, population mCRC. involvement other clinical, variables.